Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Genetic Test Reagents Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 69
ISBN Number not applicable
Product Code GMD02895

Price

£660.00
approximately: $999 | €737

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Genetic Test Reagents Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Genetic Test Reagents manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Genetic Test Reagents market categories - Genetic Test Reagents
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Genetic Test Reagents market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Genetic Test Reagents Clinical Trials
    • 2.1 Genetic Test Reagents Clinical Trial By Equipment Type
    • 2.2 Genetic Test Reagents Clinical Trials By Trial Phase and Trial Status
    • 2.3 Genetic Test Reagents Pipeline Products By Development Stage
    • 2.4 Genetic Test Reagents Pipeline Products By Therapy Area
    • 2.5 Genetic Test Reagents Pipeline Products By News Summary
    • 2.6 Genetic Test Reagents Trisomy 21 test
      • 2.6.1 Non-Invasive Screening For Fetal Aneuploidy: A New Maternal Plasma Marker
      • 2.6.2 RNA-Based Noninvasive Aneuploidy (RNA) Study
      • 2.6.3 Additional, Positive Results For Down Syndrome Test At Analyst Briefing
      • 2.6.4 Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma
      • 2.6.5 Direct, noninvasive genetic assessment of fetal Down syndrome
      • 2.6.6 Noninvasive Screening For Fetal Aneuploidy: A New Maternal Plasma Marker
      • 2.6.7 A Preliminary Study Of Noninvasive Prenatal Down Syndrome Test That Incorporates Multiple RNA Fetal Markers, Including The PLAC4 Gene
      • 2.6.8 Non-Invasive Screening For Fetal Aneuploidy: A New Maternal Plasma Marker - A Phase III LDT Study
    • 2.7 Genetic Test Reagents Noninvasive prenatal test for Rhesus D incompatibility
      • 2.7.1 A Multi-center Fetal Rhesus D (RhD) Genotype Study
      • 2.7.2 Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay
    • 2.8 Genetic Test Reagents SEQureDx Technology on the MassARRAY Platform
      • 2.8.1 Clinical Assessment of Noninvasive Screening Technology for Down Syndrome
    • 2.9 Genetic Test Reagents LungExpress Dx
      • 2.9.1 A 15-Gene Expression Signature Prognostic For Survival And Predictive For Adjuvant Chemotherapy Benefit In JBR.10 Patients
    • 2.10 Genetic Test Reagents fastFISH fetal
      • 2.10.1 Clinical Trial For Early, Non-Invasive Testing Of Down Syndrome
    • 2.11 Genetic Test Reagents DIADEP
      • 2.11.1 Proof of Concept Clinical Trial to Validate a Biological Test of Depression
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 16, 2009: Clarient Announces Launch Of EGFR Mutation Test
      • 3.1.2 Jun 09, 2009: MEDomics Introduces MitoDx For Early Diagnosis Of Mitochondrial Diseases
      • 3.1.3 Jun 03, 2009: CombiMatrix Reports Clinical Data Of HerScan Breast Cancer Test
      • 3.1.4 Jun 02, 2009: Quest Diagnostics Launches EGFR Pathway Test To Detect KRAS, NRAS, And BRAF Gene Mutations In Reflex Testing Service
      • 3.1.5 May 26, 2009: Targeted Molecular Diagnostics Introduces Novel Genetic Tests To Address Cancer Treatment
      • 3.1.6 May 25, 2009: QIAGEN Announces Launch Of QIAamp Circulating Nucleic Acid Kit For Extraction Of Free Circulating DNA And RNA Fragments
      • 3.1.7 May 11, 2009: Exiqon Diagnostics Launches KRAS Mutation Analysis For Predicting Therapeutic Response In Colorectal And Non-Small Cell Lung Cancer Patients
      • 3.1.8 May 07, 2009: Signature Genomic Laboratories Detect Pallister-Killian Syndrome Using Microarray-Based Genetic Test
      • 3.1.9 Apr 20, 2009: High Throughput Genomics Launches 96 Max Gene Expression Assay At AACR Annual Meeting
      • 3.1.10 Apr 02, 2009: Cornell University Uses Transgenomic's Nuclease And WAVE Technology For Polycystic Kidney Disease Assay
      • 3.1.11 Mar 03, 2009: PDI Launches Sequenom's Noninvasive Prenatal Screening Tests
      • 3.1.12 Feb 26, 2009: HairDX And Aderans Jointly Releases Genetic Hair Loss Test In Japan
      • 3.1.13 Feb 18, 2009: Agendia Presents MammaPrint's Breast Cancer Research And Treatment Study Results
      • 3.1.14 Feb 18, 2009: Xenomics Announces The Launch Of New Gender Prediction Test
      • 3.1.15 Feb 04, 2009: Netherlands Cancer Institute-AVL To Provide Treatment Of Breast Cancer With Agendia's MammaPrint
      • 3.1.16 Feb 03, 2009: Sequenom Presents Findings On Methylation Markers And RNA-SNP Markers At SMFM
      • 3.1.17 Jan 28, 2009: Sequenom Collaborates With Obstetrix Medical Group For LDT Validation Study
      • 3.1.18 Jan 28, 2009: Sequenom Reports Positive Results From Prospective Trial Using SEQureDx Technology
      • 3.1.19 Dec 18, 2008: CombiMatrix Announces Positive Results From Expanded HerScan Study
      • 3.1.20 Dec 16, 2008: HairDX Announced Launch Of Genetic Test Collection Kit
      • 3.1.21 Dec 13, 2008: Agendia's Breast Cancer Test MammaPrint Identifies New Subset Of Low Risk HER2+ Patients
      • 3.1.22 Dec 12, 2008: Findings Of Neoadjuvant Setting Support Predictive Power Of Mammaprint's For Chemotherapy Response
      • 3.1.23 Dec 02, 2008: Clarient Introduces Second Gene Mutation Test For Colorectal Cancer
      • 3.1.24 Dec 01, 2008: Next-Generation Noninvasive Diagnostic Technology Shown To Accurately Detect Fetal Down Syndrome In First Trimester Of Pregnancy
      • 3.1.25 Nov 18, 2008: XDx To Present At The 2008 In Vitro Diagnostic Regulatory And Reimbursement Conference
      • 3.1.26 Nov 13, 2008: Perceptronix To Exhibit At Toronto Academy Of Dentistry Annual Winter Clinic
      • 3.1.27 Nov 12, 2008: Illumina Launches Infinium HD Human660W-Quad BeadChip for Advancing Copy Number Variation Analysis Studies
      • 3.1.28 Nov 11, 2008: Major Independent Study Underscores Utility Of deCODE MI For Better Predicting Risk Of Heart Attack, Informing Statin Therapy
      • 3.1.29 Nov 10, 2008: deCODE Study Expands Clinical Utility Of deCODE AF For Improving The Diagnosis Of Atrial Fibrillation And Preventing Stroke
      • 3.1.30 Nov 10, 2008: QIAGEN Introduces CE-marked Molecular Assay For The Cancer Biomarker K-ras
      • 3.1.31 Nov 06, 2008: Illumina Launches The HumanCytoSNP-12 BeadChip
      • 3.1.32 Nov 03, 2008: American Journal Of Cardiology Describes The Use Of Progenikas LIPOchip In A Large-Scale Screening
      • 3.1.33 Oct 30, 2008: SeraCare Launches ACCURUN
      • 3.1.34 Oct 29, 2008: SeraCare Launches ACCURUN
      • 3.1.35 Oct 28, 2008: Sequenom Announces Launch Of RNA-Based Noninvasive Aneuploidy (RNA) Study
      • 3.1.36 Sep 30, 2008: CombiMatrix Launches Two New Array-Based Diagnostic Tests
      • 3.1.37 Sep 23, 2008: Sequenom Announces Additional, Positive Results For Down Syndrome Test At Analyst Briefing
      • 3.1.38 Sep 18, 2008: Agendia's MammaPrint Included In 2008 Dutch Institute For Healthcare Improvement CBO Guidelines
      • 3.1.39 Sep 15, 2008: Invitrogen, Biocare To Market FDA Approved Breast Cancer Test
      • 3.1.40 Sep 10, 2008: TrimGen Launches New KRAS Assay Test For Colon Cancer Patients
      • 3.1.41 Sep 07, 2008: Early And Accurate Detection Of Bowel Cancer With RanplexCRC
      • 3.1.42 Sep 04, 2008: Agendia Launches TargetPrint For Breast Cancer Patients
      • 3.1.43 Aug 28, 2008: Multiplex Gene Expression HD2 12x135K Microarrays Now Available From Roche NimbleGen
      • 3.1.44 Aug 27, 2008: United States Food And Drug Administration (FDA) Cleared XDx's AlloMap Gene Expression Test
      • 3.1.45 Aug 26, 2008: DiagnoCure Receives Approval From The US Regulatory Authorities And Launches Its Previstage GCC Colorectal Cancer Staging Test
      • 3.1.46 Aug 19, 2008: QIAGEN Unveils Diagnostic Assay In The EU To Detect Genetic Variation Causing Adverse Reactions In AIDS Patients
      • 3.1.47 Aug 19, 2008: The New MagNA Pure LC 2.0 System: New Design And Improved Performance Meet A Proven Nucleic Acid Isolation Technology
      • 3.1.48 Aug 18, 2008: Asuragen Launches Signature NPM1 Mutations
      • 3.1.49 Aug 13, 2008: Interleukin Genetics Licenses Its PST Genetic Test To OralDNA Labs
      • 3.1.50 Aug 06, 2008: Bio-Reference Laboratories Announces K-ras Testing Availability Through GenPath
      • 3.1.51 Jul 31, 2008: FDA Clears The Pathwork Tissue Of Origin Test For Hard-To-Identify Tumors
      • 3.1.52 Jul 22, 2008: CombiMatrix's Newly Updated Autism Test Gains Market Attention
      • 3.1.53 Jul 22, 2008: CyGene Laboratories Launches StrokeScan DNA Analysis
      • 3.1.54 Jul 22, 2008: Interleukin Genetics Launches Enhanced Heart Health Genetic Test
      • 3.1.55 Jul 15, 2008: Agendia And Ferrer Announce Exclusive Agreement For Sales Of Cancer Diagnostic Services In Four Major European Markets
      • 3.1.56 Jul 14, 2008: LabCorp Announces Availability Of ColoSure
      • 3.1.57 Jun 04, 2008: Sequenom Announces Results Of Screening Studies For Down Syndrome And Updates Development Of Noninvasive Prenatal Diagnostics At Analyst And Investor Briefing
      • 3.1.58 May 30, 2008: MammaPrint Breast Cancer Test Provides Valuable Insight For Personalized Treatment Decisions
      • 3.1.59 Feb 01, 2008: Ikonisys Initiates Clinical Trial For Early, Non-Invasive Testing Of Down Syndrome
    • 3.2 Product Approvals
      • 3.2.1 Aug 27, 2008: United States Food And Drug Administration (FDA) Cleared XDx's AlloMap Gene Expression Test
      • 3.2.2 Jul 31, 2008: FDA Clears The Pathwork Tissue Of Origin Test For Hard-To-Identify Tumors
    • 3.3 Clinical Trials
      • 3.3.1 Jun 03, 2009: CombiMatrix Reports Clinical Data Of HerScan Breast Cancer Test
      • 3.3.2 May 07, 2009: Signature Genomic Laboratories Detect Pallister-Killian Syndrome Using Microarray-Based Genetic Test
      • 3.3.3 Feb 18, 2009: Agendia Presents MammaPrint's Breast Cancer Research And Treatment Study Results
      • 3.3.4 Feb 03, 2009: Sequenom Presents Findings On Methylation Markers And RNA-SNP Markers At SMFM
      • 3.3.5 Jan 28, 2009: Sequenom Reports Positive Results From Prospective Trial Using SEQureDx Technology
      • 3.3.6 Jan 28, 2009: Sequenom Collaborates With Obstetrix Medical Group For LDT Validation Study
      • 3.3.7 Dec 18, 2008: CombiMatrix Announces Positive Results From Expanded HerScan Study
      • 3.3.8 Dec 13, 2008: Agendia's Breast Cancer Test MammaPrint Identifies New Subset Of Low Risk HER2+ Patients
      • 3.3.9 Dec 12, 2008: Findings Of Neoadjuvant Setting Support Predictive Power Of Mammaprint's For Chemotherapy Response
      • 3.3.10 Dec 01, 2008: Next-Generation Noninvasive Diagnostic Technology Shown To Accurately Detect Fetal Down Syndrome In First Trimester Of Pregnancy
      • 3.3.11 Nov 11, 2008: Major Independent Study Underscores Utility Of deCODE MI For Better Predicting Risk Of Heart Attack, Informing Statin Therapy
      • 3.3.12 Nov 10, 2008: deCODE Study Expands Clinical Utility Of deCODE AF For Improving The Diagnosis Of Atrial Fibrillation And Preventing Stroke
      • 3.3.13 Nov 03, 2008: American Journal Of Cardiology Describes The Use Of Progenikas LIPOchip In A Large-Scale Screening
      • 3.3.14 Oct 28, 2008: Sequenom Announces Launch Of RNA-Based Noninvasive Aneuploidy (RNA) Study
      • 3.3.15 Sep 23, 2008: Sequenom Announces Additional, Positive Results For Down Syndrome Test At Analyst Briefing
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Genetic Test Reagents Clinical Trial By Equipment Type
    • Table 2: Genetic Test Reagents Clinical Trials By Trial Phase and Trial Status
    • Table 3: Genetic Test Reagents Pipeline Products By Development Stage
    • Table 4: Genetic Test Reagents Pipeline Products By Therapy Area
    • Table 5: Genetic Test Reagents Pipeline Products By News Summary
    • Table 6: Trisomy 21 test - Non-Invasive Screening For Fetal Aneuploidy: A New Maternal Plasma Marker
    • Table 7: Trisomy 21 test - RNA-Based Noninvasive Aneuploidy (RNA) Study
    • Table 8: Trisomy 21 test - Additional, Positive Results For Down Syndrome Test At Analyst Briefing
    • Table 9: Trisomy 21 test - Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma
    • Table 10: Trisomy 21 test - Direct, noninvasive genetic assessment of fetal Down syndrome
    • Table 11: Trisomy 21 test - Noninvasive Screening For Fetal Aneuploidy: A New Maternal Plasma Marker
    • Table 12: Trisomy 21 test - A Preliminary Study Of Noninvasive Prenatal Down Syndrome Test That Incorporates Multiple RNA Fetal Markers, Including The PLAC4 Gene
    • Table 13: Trisomy 21 test - Non-Invasive Screening For Fetal Aneuploidy: A New Maternal Plasma Marker - A Phase III LDT Study
    • Table 14: Noninvasive prenatal test for Rhesus D incompatibility - A Multi-center Fetal Rhesus D (RhD) Genotype Study
    • Table 15: Noninvasive prenatal test for Rhesus D incompatibility - Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay
    • Table 16: SEQureDx Technology on the MassARRAY Platform - Clinical Assessment of Noninvasive Screening Technology for Down Syndrome
    • Table 17: LungExpress Dx - A 15-Gene Expression Signature Prognostic For Survival And Predictive For Adjuvant Chemotherapy Benefit In JBR.10 Patients
    • Table 18: fastFISH fetal - Clinical Trial For Early, Non-Invasive Testing Of Down Syndrome
    • Table 19: DIADEP - Proof of Concept Clinical Trial to Validate a Biological Test of Depression
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology